202 related articles for article (PubMed ID: 29372612)
1. Statins decrease leptin expression in human white adipocytes.
Singh P; Zhang Y; Sharma P; Covassin N; Soucek F; Friedman PA; Somers VK
Physiol Rep; 2018 Jan; 6(2):. PubMed ID: 29372612
[TBL] [Abstract][Full Text] [Related]
2. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake.
Mäuser W; Perwitz N; Meier B; Fasshauer M; Klein J
Eur J Pharmacol; 2007 Jun; 564(1-3):37-46. PubMed ID: 17376428
[TBL] [Abstract][Full Text] [Related]
3. The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study.
Mueller AM; Liakoni E; Schneider C; Burkard T; Jick SS; Krähenbühl S; Meier CR; Spoendlin J
J Gen Intern Med; 2021 Sep; 36(9):2639-2647. PubMed ID: 33751411
[TBL] [Abstract][Full Text] [Related]
4. Intensive Statin Therapy Compromises the Adiponectin-AdipoR Pathway in the Human Monocyte-Macrophage Lineage.
Gasbarrino K; Hafiane A; Zheng H; Daskalopoulou SS
Stroke; 2019 Dec; 50(12):3609-3617. PubMed ID: 31648632
[TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity of statins and other lipid-lowering agents.
Björnsson ES
Liver Int; 2017 Feb; 37(2):173-178. PubMed ID: 27860156
[TBL] [Abstract][Full Text] [Related]
6. Statin treatment and new-onset diabetes: a review of proposed mechanisms.
Brault M; Ray J; Gomez YH; Mantzoros CS; Daskalopoulou SS
Metabolism; 2014 Jun; 63(6):735-45. PubMed ID: 24641882
[TBL] [Abstract][Full Text] [Related]
7. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Curr Med Res Opin; 2008 Jul; 24(7):1987-2000. PubMed ID: 18554430
[TBL] [Abstract][Full Text] [Related]
8. TNF-α modulates statin effects on secretion and expression of MCP-1, PAI-1 and adiponectin in 3T3-L1 differentiated adipocytes.
Lobo SM; Quinto BM; Oyama L; Nakamichi R; Ribeiro AB; Zanella MT; Dalboni MA; Batista MC
Cytokine; 2012 Oct; 60(1):150-6. PubMed ID: 22658637
[TBL] [Abstract][Full Text] [Related]
9. Cognitive impairment associated with atorvastatin and simvastatin.
King DS; Wilburn AJ; Wofford MR; Harrell TK; Lindley BJ; Jones DW
Pharmacotherapy; 2003 Dec; 23(12):1663-7. PubMed ID: 14695047
[TBL] [Abstract][Full Text] [Related]
10. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlled, randomized trial.
Abbasi SH; Mohammadinejad P; Shahmansouri N; Salehiomran A; Beglar AA; Zeinoddini A; Forghani S; Akhondzadeh S
J Affect Disord; 2015 Sep; 183():149-55. PubMed ID: 26005776
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
[TBL] [Abstract][Full Text] [Related]
12. [Statin-related drug-induced liver injury].
Li XY; Zhong W; Mao YM
Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):659-663. PubMed ID: 37400395
[TBL] [Abstract][Full Text] [Related]
13. Statins Promote Interleukin-1β-Dependent Adipocyte Insulin Resistance Through Lower Prenylation, Not Cholesterol.
Henriksbo BD; Tamrakar AK; Xu J; Duggan BM; Cavallari JF; Phulka J; Stampfli MR; Ashkar AA; Schertzer JD
Diabetes; 2019 Jul; 68(7):1441-1448. PubMed ID: 31010959
[TBL] [Abstract][Full Text] [Related]
14. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P;
Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288
[TBL] [Abstract][Full Text] [Related]
15. Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study.
Dave CV; Winterstein AG; Park H; Cook RL; Hartzema AG
J Affect Disord; 2018 Oct; 238():542-546. PubMed ID: 29936394
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin and atorvastatin reduce the mechanical properties of tendon constructs in vitro and introduce catabolic changes in the gene expression pattern.
Eliasson P; Svensson RB; Giannopoulos A; Eismark C; Kjær M; Schjerling P; Heinemeier KM
PLoS One; 2017; 12(3):e0172797. PubMed ID: 28264197
[TBL] [Abstract][Full Text] [Related]
17. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
[TBL] [Abstract][Full Text] [Related]
18. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle.
Laaksonen R; Katajamaa M; Päivä H; Sysi-Aho M; Saarinen L; Junni P; Lütjohann D; Smet J; Van Coster R; Seppänen-Laakso T; Lehtimäki T; Soini J; Oresic M
PLoS One; 2006 Dec; 1(1):e97. PubMed ID: 17183729
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin monotherapy as a potential option for statin-associated muscle symptoms: a case report.
Qu H; Guo M; Kou N; Wu HT; Zhang Y; Gao ZY; Shi DZ
J Clin Pharm Ther; 2016 Oct; 41(5):568-71. PubMed ID: 27425755
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation.
Maeda T; Horiuchi N
J Biochem; 2009 Jun; 145(6):771-81. PubMed ID: 19254925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
